<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67194">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982539</url>
  </required_header>
  <id_info>
    <org_study_id>81-0072</org_study_id>
    <nct_id>NCT01982539</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute</brief_title>
  <official_title>An Open-Label Study of the Safety and Efficacy of Zipsor® (Diclofenac Potassium) Liquid Filled Capsules in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Depomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Depomed</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As part of the PREA(Pediatric Research Equity Act) commitment, the objective of the study is
      to confirm safety and tolerability of 25 mg of Zipsor® in clinical pediatric subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label study, subjects will be dosed with Zipsor® for the treatment of mild to moderate
      acute pain for up to 4 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To confirm the safety and tolerability of Zipsor® in pediatric subjects, ages 12 to 17 years</measure>
    <time_frame>up to 4-days of Zipsor treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety Endpoints:
Treatment emergent AEs (TEAEs)
Serious adverse events (SAEs)
Withdrawals due to AEs
Deaths
Observed values and changes in vital sign measurements
Observed values and changes in clinical laboratory results
Physical examination findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>From Baseline to 1st and 2nd hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine efficacy by assessing percent changes of the Numeric Pain Rating Scale (NPRS) pain score from baseline to (1) the first hour and (2) the second hour after the first dose of Zipsor® administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Zipsor® (Liquid filled capsules)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg/every 6hrs/up to 4 days treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zipsor®</intervention_name>
    <description>Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.</description>
    <arm_group_label>Zipsor® (Liquid filled capsules)</arm_group_label>
    <other_name>Diclofenac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between 12-17 years of age.

          -  Subjects must be post-op, having mild or moderate acute pain.

        Other inclusions apply.

        Exclusion Criteria:

          -  Subject has a known history of allergic reaction, hypersensitivity to diclofenac,
             aspirin, acetaminophen, or reaction to the non-active ingredients of the study
             medication.

          -  Subject has been taking analgesic for 48-72 hours prior to Screening.

          -  Subject has a history of any GI event greater than 6 months before Screening.

          -  Subject is currently receiving any medication that is contraindicated for use
             concomitantly with diclofenac or acetaminophen.

          -  Subject has previously participated in another clinical study of Zipsor or taking
             Zipsor for any other indication.

          -  Subject is requiring treatment for pre-existing hypertension.

        Other exclusions apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>NSAID</keyword>
  <keyword>moderate pain</keyword>
  <keyword>mild pain</keyword>
  <keyword>acute pain</keyword>
  <keyword>mild acute pain</keyword>
  <keyword>moderate acute pain</keyword>
  <keyword>mild or moderate acute pain</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
